

Raw Material/Catalyst Preparation
100
Polymer Manufacture Process
105
Granular Drug Formulation Process
110
Loading of Granular Drug Formulation into Polymer
115
Ring Formation
120

Figure 1



% Residual Potency and Release
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
25
Time (Days)
QH12001 RLST0027
QH12002 RLST0047
QH12003 RLST0072
QH12004 RLST1015
QH12005 RLST0098
QH12006 RLST0044

Figure 2



QH13009 (n=3); (RLST0183, Avicel/Quin Blend); ~1.5g Block; 0.05% w/w
QH13048, RLST0157, ~1500mg Block, 0.05% w/w (n=3)
% Release
Time (days)
0
5
10
15
20
25
30
0
1
2
3
4
5
6
7
8
9
10
11
12
13

Figure 3



% Residual Potency and Release
100
90
80
70
60
50
40
30
20
10
0
0
5
10
15
20
25
Time (Days)
QH12012 RLST0072
QH12013 RLST0154

Figure 4



% Release and Residual Potency
0
10
20
30
40
50
60
70
80
Time (Days)
0
1
2
3
4
5
6
7
8
9
10
QH12012 R1ST0072
QH12013 R1ST0154
QH12024 R1ST0156
QH12025 R1ST0155

Figure 5



% Residual Potency and Release
60
50
40
30
20
10
0
0
5
10
15
20
Time (Days)
QH12019 RLST0044
QH12020 RLST0072
QH12022 RLST0072

Figure 6



Mean Quinagolide HCl released (mcg)
1500
1300
1100
900
700
500
300
100
-100
0
5
10
15
20
25
Time (Days)
QH12020 In-Vivo
QH12020 In-Vitro
QH12022 In-Vivo
QH12022 In-Vitro

Figure 7



Mean Quinagolide HCl Released (mcg)
600
500
400
300
200
100
0
0
3
6
9
12
15
18
21
24
27
Time (Days)
QH13005 In-Vivo
QH13005 In-Vitro
QH13006 In-Vivo
QH13006 In-Vitro

Figure 8



QH12020 RLST0072
QH12022 RLST0072
QH13005 RLST0157
QH13006 RLST0157
Mean Quinagolide HCl Released (mcg/Day)
100
80
60
40
20
0
1
4
7
10
13
16
19
22
25
28
Time (Days)

Figure 9



○ QH12022
□ QH12020
Δ QH 13006
Q, M1, M2
M2
Q
Conc Q, M1,M2 (pg/mL)
100
10
1
0.1
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Figure 10



% Release and Residual Potency
Time (Days)
0
5
10
15
20
25
30
35
40
0
5
10
15
20
25
QH13017 RLST0072+RLST0072 Coat, Thickness 1
QH13018 RLST0072+RLST0047 Coat, Thickness 1
QH13019 RLST0072+RLST0046 Coat, Thickness 1
QH13020 RLST0072+RLST0046 Coat, Thickness 1
QH13021 RLST0072+RLST0046 Coat, Thickness 2
QH13022 RLST0072+RLST0047 Coat, Thickness 2
QH13023 RLST0072+RLST0072 Coat, Thickness 2
QH13024 RLST0072, Control

Figure 11





Figure 12 A, B and C






Figure 13



Median Q Conc (pg/mL)
10
1
0.1
0
7
14
21
28
35
Nominal_time (day)
Black line
Red line
Blue line

Figure 14



10
1
0.1
Mean (pg/mL)
0
7
14
21
28
35
Nominal_elapsed_time_from_Insertion (day)
Black line
Red line
Blue line

Figure 15



0
28
56
84
Cycle 1
Cycle 2
Cycle 3
1st Drug-device unit insertion
1st Drug-device unit removal
2nd Drug-device unit insertion
2nd Drug-device unit removal
3rd Drug-device unit insertion

Figure 16